1-20 of 23
Markolf Hanefeld
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39: 2026–2035

Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies, on behalf of the LixiLan-O Trial Investigators
Journal: Diabetes Care
Diabetes Care 2017;40(6):809
https://doi.org/10.2337/dc17-er06c
Published: 18 April 2017
View article titled, Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39: 2026–2035
Open the PDF for Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39: 2026–2035 in another window
Journal Articles

Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114

Jens Jordan, Ali El-Armouche, Markolf Hanefeld, Stefan R. Bornstein, Andreas L. Birkenfeld
Journal: Diabetes Care
Diabetes Care 2016;39(12):e224–e225
https://doi.org/10.2337/dc16-1588
Published: 10 November 2016
View article titled, Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114
Open the PDF for Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114 in another window
Journal Articles

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies, on behalf of the LixiLan-O Trial Investigators
Journal: Diabetes Care
Diabetes Care 2016;39(11):2026–2035
https://doi.org/10.2337/dc16-0917
Published: 15 August 2016
View article titled, Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
Open the PDF for Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Hypoglycemia and Cardiovascular Risk: Is There a Major Link?

Markolf Hanefeld, Brian M. Frier, Frank Pistrosch
Journal: Diabetes Care
Diabetes Care 2016;39(Supplement_2):S205–S209
https://doi.org/10.2337/dcS15-3014
Published: 16 July 2016
View article titled, Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
Open the PDF for Hypoglycemia and Cardiovascular Risk: Is There a Major Link? in another window
Journal Articles

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

Julio Rosenstock, Bruno Guerci, Markolf Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J. Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardecki, Jenny Ye, Riccardo Perfetti, Simon Heller
Journal: Diabetes Care
Diabetes Care 2016;39(8):1318–1328
https://doi.org/10.2337/dc16-0014
Published: 23 May 2016
View article titled, Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
Open the PDF for Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial in another window
Includes: Supplementary data
Journal Articles

Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias

Annett Stahn, Frank Pistrosch, Xenia Ganz, Madlen Teige, Carsta Koehler, Stefan Bornstein, Markolf Hanefeld
Journal: Diabetes Care
Diabetes Care 2014;37(2):516–520
https://doi.org/10.2337/dc13-0600
Published: 11 January 2014
View article titled, Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias
Open the PDF for Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias in another window
Includes: Supplementary data
Journal Articles

Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)

Eva M. Lonn, MD, Jackie Bosch, MSC, Rafael Diaz, MD, Patricio Lopez-Jaramillo, MD, Ambady Ramachandran, MD, Nicolae Hâncu, MD, PHD, Markolf Hanefeld, MD, Henry Krum, MBBS, PHD, Lars Ryden, MD, PHD, Sandra Smith, RDMS, Matthew J. McQueen, MD, PHD, Leanne Dyal, MSC, Salim Yusuf, MD, DPHIL, Hertzel C. Gerstein, MD, for the GRACE and ORIGIN Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(9):2466–2474
https://doi.org/10.2337/dc12-2129
Published: 13 August 2013
View article titled, Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: <subtitle>The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)</subtitle>
Open the PDF for Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: <subtitle>The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

David Russell-Jones, MD, Robert M. Cuddihy, MD, Markolf Hanefeld, MD, Ajay Kumar, MD, Jose G. González, MD, Melanie Chan, PHD, Anne M. Wolka, PHD, Marilyn K. Boardman, PHARMD, on behalf of the DURATION-4 Study Group
Journal: Diabetes Care
Diabetes Care 2012;35(2):252–258
https://doi.org/10.2337/dc11-1107
Published: 16 January 2012
View article titled, Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): <subtitle>A 26-week double-blind study</subtitle>
Open the PDF for Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): <subtitle>A 26-week double-blind study</subtitle> in another window
Includes: Supplementary data
Journal Articles

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study

Michael R. MacDonald, MD, Mark C. Petrie, MD, Philip D. Home, DM, Michel Komajda, MD, Nigel P. Jones, MA, Henning Beck-Nielsen, DMSC, Ramon Gomis, MD, Markolf Hanefeld, MD, Stuart J. Pocock, PHD, Paula S. Curtis, PHD, John J.V. McMurray, MD
Journal: Diabetes Care
Diabetes Care 2011;34(6):1394–1396
https://doi.org/10.2337/dc10-2398
Published: 20 May 2011
View article titled, Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: <subtitle>A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study</subtitle>
Open the PDF for Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: <subtitle>A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study</subtitle> in another window
Journal Articles

Is Hyperglycemia a Cardiovascular Risk Factor?

Frank Pistrosch, MD, Andrea Natali, MD, Markolf Hanefeld, MD
Journal: Diabetes Care
Diabetes Care 2011;34(Supplement_2):S128–S131
https://doi.org/10.2337/dc11-s207
Published: 22 April 2011
View article titled, Is Hyperglycemia a Cardiovascular Risk Factor?
Open the PDF for Is Hyperglycemia a Cardiovascular Risk Factor? in another window
Journal Articles

Shifting the Disease Management Paradigm From Glucose: What are the cons?

Markolf Hanefeld, MD, Stefan R. Bornstein, MD, Frank Pistrosch, MD
Journal: Diabetes Care
Diabetes Care 2009;32(suppl_2):S353–S356
https://doi.org/10.2337/dc09-S338
Published: 01 November 2009
View article titled, Shifting the Disease Management Paradigm From Glucose: <subtitle>What are the cons?</subtitle>
Open the PDF for Shifting the Disease Management Paradigm From Glucose: <subtitle>What are the cons?</subtitle> in another window
Journal Articles

Evaluation of a Diabetes Management System Based on Practice Guidelines, Integrated Care, and Continuous Quality Management in a Federal State of Germany: A population-based approach to health care research

Ulrike Rothe, MD, Gabriele Müller, MPH, Peter E.H. Schwarz, MD, Martin Seifert, MSC, Hildebrand Kunath, PHD, MD, Rainer Koch, PHD, Sybille Bergmann, PHD, Ulrich Julius, PHD, MD, Stefan R. Bornstein, PHD, MD, Markolf Hanefeld, PHD, MD, Jan Schulze, PHD, MD
Journal: Diabetes Care
Diabetes Care 2008;31(5):863–868
https://doi.org/10.2337/dc07-0858
Published: 01 May 2008
View article titled, Evaluation of a Diabetes Management System Based on Practice Guidelines, Integrated Care, and Continuous Quality Management in a Federal State of Germany: <subtitle>A population-based approach to health care research</subtitle>
Open the PDF for Evaluation of a Diabetes Management System Based on Practice Guidelines, Integrated Care, and Continuous Quality Management in a Federal State of Germany: <subtitle>A population-based approach to health care research</subtitle> in another window
Journal Articles

Natural History of Cardiovascular Disease in Patients With Diabetes: Role of hyperglycemia

Zvonko Milicevic, MD, PHD, Itamar Raz, MD, Scott D. Beattie, PHD, Barbara N. Campaigne, PHD, Samiha Sarwat, MS, Elwira Gromniak, MD, Irina Kowalska, MD, Edvard Galic, MD, Meng Tan, MD, Markolf Hanefeld, MD, PHD
Journal: Diabetes Care
Diabetes Care 2008;31(Supplement_2):S155–S160
https://doi.org/10.2337/dc08-s240
Published: 01 February 2008
View article titled, Natural History of Cardiovascular Disease in Patients With Diabetes: <subtitle>Role of hyperglycemia</subtitle>
Open the PDF for Natural History of Cardiovascular Disease in Patients With Diabetes: <subtitle>Role of hyperglycemia</subtitle> in another window
Journal Articles

The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes: Response to Kilpatrick et al.

Louis Monnier, MD, Claude Colette, PHD, Lawrence Leiter, MD, Antonio Ceriello, MD, Markolf Hanefeld, MD, David Owens, MD, Naoko Tajima, MD, Jaakko Tuomiletho, MD, Jaime Davidson, MD, On Behalf of the PGR Group
Journal: Diabetes Care
Diabetes Care 2007;30(1):185–186
https://doi.org/10.2337/dc06-1594
Published: 01 January 2007
View article titled, The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes: <subtitle>Response to Kilpatrick et al.</subtitle>
Open the PDF for The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes: <subtitle>Response to Kilpatrick et al.</subtitle> in another window
Journal Articles

Hypoadiponectinemia Is Associated With Progression Toward Type 2 Diabetes and Genetic Variation in the ADIPOQ Gene Promoter

Peter E.H. Schwarz, MD, Gordon W. Towers, PHD, Sabine Fischer, MD, Suresh Govindarajalu, MD, Jan Schulze, MD, Stephan R. Bornstein, MD, Markolf Hanefeld, MD, Francis Vasseur, MD
Journal: Diabetes Care
Diabetes Care 2006;29(7):1645–1650
https://doi.org/10.2337/dc05-2123
Published: 01 July 2006
View article titled, Hypoadiponectinemia Is Associated With Progression Toward Type 2 Diabetes and Genetic Variation in the <em>ADIPOQ</em> Gene Promoter
Open the PDF for Hypoadiponectinemia Is Associated With Progression Toward Type 2 Diabetes and Genetic Variation in the <em>ADIPOQ</em> Gene Promoter in another window
Journal Articles

α-Glucosidase Inhibitors for Patients With Type 2 Diabetes: Response to van de Laar et al.

Markolf Hanefeld, MD, PHD, Robert G. Josse, MBBS, Jean-Louis Chiasson, MD
Journal: Diabetes Care
Diabetes Care 2005;28(7):1840
https://doi.org/10.2337/diacare.28.7.1840
Published: 01 July 2005
View article titled, α-Glucosidase Inhibitors for Patients With Type 2 Diabetes: <subtitle>Response to van de Laar et al.</subtitle>
Open the PDF for α-Glucosidase Inhibitors for Patients With Type 2 Diabetes: <subtitle>Response to van de Laar et al.</subtitle> in another window
Journal Articles

In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control

Frank Pistrosch, MD, Jens Passauer, MD, Sabine Fischer, MD, Katja Fuecker, Markolf Hanefeld, MD, Peter Gross, MD
Journal: Diabetes Care
Diabetes Care 2004;27(2):484–490
https://doi.org/10.2337/diacare.27.2.484
Published: 01 February 2004
View article titled, In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control
Open the PDF for In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control in another window
Journal Articles

One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes

Markolf Hanefeld, MD, PHD, Paolo Brunetti, MD, Guntram H. Schernthaner, MD, David R. Matthews, FRCP, MA, Bernard H. Charbonnel, MD, on behalf of the QUARTET Study Group
Journal: Diabetes Care
Diabetes Care 2004;27(1):141–147
https://doi.org/10.2337/diacare.27.1.141
Published: 01 January 2004
View article titled, One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes
Open the PDF for One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes in another window
Journal Articles

Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study

Markolf Hanefeld, MD, PHD, Carsta Koehler, PHD, Katja Fuecker, DIPL CHEM, Elena Henkel, MD, Frank Schaper, MD, Theodora Temelkova-Kurktschiev, MD, PHD
Journal: Diabetes Care
Diabetes Care 2003;26(3):868–874
https://doi.org/10.2337/diacare.26.3.868
Published: 01 March 2003
View article titled, Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: <subtitle>The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study</subtitle>
Open the PDF for Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: <subtitle>The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study</subtitle> in another window
Journal Articles

The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data

Jean-Louis Chiasson, MD, Roman Gomis, MD, Markolf Hanefeld, DSC, Robert G Josse, MBBS, Avraham Karasik, MD, Markku Laakso, MD, The Stop-Niddm Trial Research Group
Journal: Diabetes Care
Diabetes Care 1998;21(10):1720–1725
https://doi.org/10.2337/diacare.21.10.1720
Published: 01 October 1998
View article titled, The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data
Open the PDF for The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data in another window